

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application : Anthony H. Cincotta
Serial No. :
Filed :
For : HEREWITH
METHODS OF TREATING METABOLIC
SYNDROME USING DOPAMINE
RECEPTOR AGONISTS

Examiner :
Attorney Docket : 102546-100
Group Art Unit :
Confirmation No. :
Customer No. : 27267

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on 08 APR 2004.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. A copy of each reference (if not previously submitted) is enclosed. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- [X] 1. This Information Disclosure Statement is being filed within three months of the U. S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
- ☐ b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
- ☐ Please charge Deposit Account No. 23-1665 in the amount of \$240.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
- ☐ A check in the amount of \$240.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
- ☐ a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- ☐ b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ Please charge Deposit Account No. 23-1665 in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- ☐ A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

ANTHONY H. CINCOTTA

Date: 08 APR 2004

By: Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant

WIGGIN AND DANA LLP
One Century Tower
New Haven, CT 06508-1832

Telephone : (203) 498-4400
Telecopier: (203) 782-2889

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Anthony H. Cincotta
Serial No. :
Filed : HEREWITH
For : METHODS OF TREATING METABOLIC
SYNDROME USING DOPAMINE
RECEPTOR AGONISTS

Examiner :
Attorney Docket : 102546-100
Group Art Unit :
Confirmation No. :
Customer No. : 27267

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on 08 APR 2004.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant

INFORMATION DISCLOSURE LETTER

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

1. United States Patent No. 6,506,799 B1 (DASSEUX, JEAN-LOUIS HENRI) 14 January 2003 (2003-01-14).
2. United States Patent No. 6,441,036 B1 (BERGE, ROLF) 27 August 2002 (2002-08-27).
3. United States Patent No. 6,410,339 B1 (MÄRIN, PER) 25 June 2002 (2002-06-25).
4. United States Patent No. 6,376,464 B1 (DASSEUX, JEAN-LOUIS, ET AL.) 23, April 2002 (2002-04-23).
5. United States Patent No. 6,322,976 B1 (ALTMAN, TIMOTHY J., ET AL.) 27 November 2001 (2001-11-27).
6. United States Patent No. 6,197,765 B1 (VARDI, PNINA and MORAD, LATIFA) 6 March 2001 (2001-03-06).
7. United States Patent No. 6,166,017 (MARIN, PER) 26 December 2000 (2000-12-26).
8. United States Patent No. 6,040,292 (SOMMER, ANDREAS) 21 March 2000 (2000-03-21).
9. United States Patent No. 6,004,972 (CINCOTTA, ANTHONY H. and MEIER, ALBERT H.) 21 December 1999 (1999-12-21).
10. United States Patent No. 5,877,183 (CINCOTTA, ANTHONY H.) 2 March 1999 (1999-03-02).
11. United States Patent No. 5,866,584 (CINCOTTA, ANTHONY H. and MEIER, ALBERT H.) 2 February 1999 (1999-02-02).
12. United States Patent No. 5,756,513 (CINCOTTA, ANTHONY H. and MEIER, ALBERT H.) 26 May 1998 (1998-05-26).
13. United States Patent No. 5,741,503 (CINCOTTA, ANTHONY H., ET AL.) 21 April 1998 (1998-04-21).
14. United States Patent No. 5,468,755 (CINCOTTA, ANTHONY H. and MEIER, ALBERT H.) 21 November 1995 (1995-11-21).

Applicant submits that copies of the above-cited references are enclosed herewith.

If the Examiner has any questions or feels that a discussion with Applicant's representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicant's undersigned representative at the telephone number listed below.

Respectfully submitted,

ANTHONY H. CINCOTTA

Date: 08 MAR 2004

By: Todd E. Garabedian

Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant

WIGGIN AND DANA LLP
One Century Tower
P. O. Box 1832
New Haven, CT 06508-1832
Telephone: (203) 498-4400
Fax: (203) 782-2889

\\15546\\8\\45353.1

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			ATTY. DOCKET NO. 102546-100		SERIAL NO.	
			APPLICANT: ANTHONY H. CINCOTTA			
			FILING DATE: HEREWITH		GROUP:	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPR.
	6,506,799 B1	01-14-2003	Dasseux, J.-L. H.	A61K	31/075	
	6,441,036 B1	08-27-2002	Berge, Rolf	A01N	37/02	
	6,410,339 B1	06-25-2002	Märin, Per	G01N	33/53	
	6,376,464 B1	04-23-2002	Dasseux, J.-L., et al.	A61K	38/00	
	6,322,976 B1	11-27-2001	Altman, T. J., et al.	C12Q	1/68	
	6,197,765 B1	03-06-2001	Vardi, P., et al.	A61K	31/5415	
	6,166,017	12-26-2000	Marin, Per	A61K	31/50	
	6,040,292	03-21-2000	Sommer, Andreas	A61K	38/00	
	6,004,972	12-21-1999	Cincotta, A.H., et al.	A61K	31/44	
	5,877,183	03-02-1999	Cincotta, A.H.	A61K	31/44	
	5,866,584	02-02-1999	Cincotta, A.H., et al.	A61K	31/44	
	5,756,513	05-26-1998	Cincotta, A.H., et al.	A61K	31/44	
	5,741,503	04-21-1998	Cincotta, A.H., et al.	A61F	2/02	
	5,468,755	11-21-1995	Cincotta, A.H., et al.	A61K	31/44	
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
EXAMINER:				DATE CONSIDERED:		
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>\15546\8\45356.1</p>						